iBio receives patent from China for anthrax antibody

iBio, Inc., announced on Monday that it recently received a Chinese patent for the composition and production of a human monoclonal antibody used in the treatment of anthrax.

Anthrax is a disease caused by the bacterium called Bacillus anthracis. Most versions of the disease are lethal and are known to affect both humans and animals. The anthrax spores can be produced and used as a biological weapon.

The claims used in the patent cover human monoclonal antibody and specifically recognize the cell binding protein known as a protective antigen of Bacillus anthracis. In studies, the antibody prevented death in mouse and non-human primates in 100 percent of the cases.

"This invention may be of significant interest to the Chinese government and other governmental entities who may determine, in a manner similar to the United States, that stockpiling antibody for the treatment of this potential infection is a national security priority," Robert Erwin, president of iBio, said.

In addition to the use of this antibody for use against anthrax, iBio is also is using its iBioLaunch technology to further the development of anthrax vaccine candidates.

iBio develops product applications of its iBioLaunch and iBioModulator platforms. The technology is used in the advancement of vaccine development and production.